Your browser doesn't support javascript.
loading
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Kwon, Minsuk; Kim, Gahyun; Kim, Ryul; Kim, Kyu-Tae; Kim, Seung Tae; Smith, Simon; Mortimer, Peter G S; Hong, Jung Yong; Loembé, Arsene-Bienvenu; Irurzun-Arana, Itziar; Koulai, Loumpiana; Kim, Kyoung-Mee; Kang, Won Ki; Dean, Emma; Park, Woong-Yang; Lee, Jeeyun.
Affiliation
  • Kwon M; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Kim G; Department of Hematology-Oncology, Ajou University, Suwon, Republic of Korea.
  • Kim R; Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Kim KT; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea.
  • Kim ST; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Smith S; Department of Physiology, Ajou University, Suwon, Republic of Korea.
  • Mortimer PGS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Hong JY; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Loembé AB; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Irurzun-Arana I; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Koulai L; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Kim KM; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Kang WK; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Dean E; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Park WY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Lee J; Oncology R&D, AstraZeneca, Cambridge, UK.
J Immunother Cancer ; 10(7)2022 07.
Article in En | MEDLINE | ID: mdl-35790315
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2022 Type: Article